BMY

Bristol‑Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets prescription medicines, primarily in oncology, hematology, immunology, cardiovascular disease and neuroscience. It operates in the pharmaceutical sector as a research‑driven drug manufacturer, selling products such as Opdivo, Breyanzi, Revlimid (historically) and newer launches like Sotyktu and Camzyos. The firm has built a leading market position through a combination of internal R&D and strategic acquisitions, notably Celgene, MyoKardia and Mirati, giving it a deep pipeline of late‑stage candidates and a broad portfolio across multiple therapeutic areas.